<DOC>
	<DOC>NCT02100514</DOC>
	<brief_summary>This study is a multicenter, double-blind, randomized study to access the efficacy, safety and tolerability of Bococizumab (PF-04950615; RN316) in subjects with hyperlipidemia receiving background statin therapy.</brief_summary>
	<brief_title>Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<criteria>Treated with a statin Fasting LDLC &gt;=100 mg/dL and triglyceride &lt;= 400 mg/dL High or very high risk of incurring a cardiovascular event Pregnant or breastfeeding females Cardiovascular or cerebrovascular event or procedure within 90 days Congestive heart failure NYHA class IV Poorly controlled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Primary hyperlipidemia or mixed dyslipidemia</keyword>
	<keyword>high risk of cardiovascular events</keyword>
	<keyword>multiple cardiovascular disease risk factors.</keyword>
</DOC>